1 Introduction Obstructive sleep apnea syndrome (OSAS) is a chronic sleep-related breathing disorder characterized by recurrent upper airway collapse during sleep, leading to intermittent hypoxemia, sleep architecture disruption, and impaired daytime functioning ( Obesity is among the most important modifiable risk factors for OSAS
Contrave carries more serious cardiovascular and neuropsychiatric warnings
Biological actions of GLP-1, source: reference [1] Evolution of GLP1 GLP-1RAs Currently, there are nine GLP-1RAs approved for marketing worldwide (Table 1), mainly for the treatment of diabetes and obesity, of which tirzepatide is a novel dual GLP-1RA/GIPR agonist
Ready to take charge of your weight and your health
In California, 503A compounding pharmacies may only prepare GLP-1 medications when a patient has an intolerance to FDA-approved versions like Wegovy , Ozempic , Zepbound , or Mounjaro